ArticleFrontiers in oncology2023

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from

Francesca Sofia Di Lisa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.